Swedish Medical Equipment Stock News

Lagercrantz Group (OM:LAGR B) released its second-quarter earnings, showing sales and net income grew compared to last year. The latest financial results have drawn greater investor focus to the company’s ongoing performance. See our latest analysis for Lagercrantz Group. Lagercrantz Group’s robust second-quarter results come after a strong run in the share price, which is now SEK 233.4. Momentum has accelerated lately, with a 13.4% share price return over the past month and an 11% gain...

Bufab AB (publ) recently reported third-quarter and nine-month 2025 earnings, with sales reaching SEK 1,917 million and net income of SEK 142 million for the quarter ended September 30, 2025. Although third-quarter profits slipped slightly year-on-year, the company saw improved net income over the nine-month period, suggesting resilient longer-term performance. We'll examine how Bufab's nine-month net income improvement and steady sales impact the company's investment narrative and future...

Essity (OM:ESSITY B) unveiled a sweeping business reorganization and updated investors with third-quarter results on the same day, signaling dramatic changes designed to boost profitable growth and streamline operations over the next year. See our latest analysis for Essity. Essity’s shakeup comes after a challenging year for shareholders, with the latest share price at SEK 260.9 and a year-to-date price return of -12.2%. Still, recent momentum is building as the share price has climbed over...

Addtech AB (publ.) (OM:ADDT B) just released its latest earnings, providing investors with a closer look at how the business is progressing. The company reported higher sales and net income for both the second quarter and first half of the fiscal year. See our latest analysis for Addtech AB (publ.). Building on this momentum, Addtech AB (publ.) has seen its share price climb nearly 6% over the past month and deliver a solid 8% total return over the past year. The share price’s positive move...

AB Electrolux (publ) recently released its third quarter and nine-month 2025 results, reporting sales of SEK32.32 billion and SEK96.17 billion, respectively, along with net income of SEK192 million for the quarter and SEK412 million for the period, marking a significant return to profitability from previous losses. This earnings turnaround highlights operational improvements that reversed a net loss trend for both the quarter and the year-to-date period. With Electrolux posting profits after...

On October 23, 2025, Evolution AB released its third quarter results, reporting revenue of €507.12 million and net income of €252.33 million, both below the figures posted a year earlier. This marks a rare year-over-year decline in revenue and net income for Evolution, despite ongoing efforts to expand in regulated markets and enhance product offerings. Now, we'll examine how this decreased revenue and net income may affect Evolution's long-term investment outlook and risk profile. Trump's...

Dometic Group AB (publ) recently announced that Chief Financial Officer Stefan Fristedt will depart by the end of April 2026, while also reporting third-quarter 2025 earnings showing a return to profitability compared to a net loss a year earlier, despite a drop in sales to SEK 4,885 million. This combination of executive transition and improved earnings performance, following a previous period of losses, raises important questions about the company's future direction and continuity. We'll...

Lifco AB reported strong third-quarter 2025 results, with sales rising to SEK 6,842 million and net income increasing to SEK 892 million compared to the previous year. Management highlighted Lifco’s continued low net debt to EBITDA ratio of 1.3x and emphasized an ongoing commitment to acquisitions across Europe to support future development. We’ll assess how Lifco’s solid financial position and ongoing acquisition activity could influence its previously established growth outlook. Outshine...

Vitrolife (OM:VITR) has just released its third quarter and nine-month 2025 earnings, showing lower sales and net income compared to last year. Investors are watching to understand what these results mean for future performance. See our latest analysis for Vitrolife. Vitrolife’s share price has struggled to regain momentum, with a year-to-date decline of nearly 33% and a 1-year total shareholder return of -36%. Even as the stock saw a modest 7% gain in the past month, this pattern suggests...

Fastighets AB Balder (OM:BALD B) caught investor attention after announcing a swing to profit for both the third quarter and the nine-month period. The company reversed last year’s losses and reported higher sales and net income. See our latest analysis for Fastighets AB Balder. Balder’s turnaround story has set a positive tone, but the market response has been mixed. The stock’s share price is up 5.3% over the last month, while the total shareholder return for the past year remains down...

Vimian Group (OM:VIMIAN) just released third quarter results showing higher sales and a move from net loss to net profit. The earnings come alongside an update on their increased M&A efforts. See our latest analysis for Vimian Group. Despite stronger earnings and a ramp-up in their M&A strategy, Vimian Group’s momentum has yet to sway the market. The share price is down 25.2% year-to-date and the one-year total shareholder return sits at negative 31.6%. While short-term price moves have been...

BioArctic AB’s partner Eisai recently announced that Health Canada granted a Notice of Compliance with Conditions for Leqembi® (lecanemab), the first Alzheimer’s treatment in Canada targeting an underlying cause of the disease, while BioArctic reported a 68% year-over-year increase in royalties from global Leqembi sales for Q3 2025, totaling SEK117.2 million. The conditional Canadian approval, which expands Leqembi’s reach, comes as the drug’s successful commercialization and significant...

Sweco (OM:SWEC B) has caught the market’s eye after reporting higher revenue and profit for the third quarter and first nine months of 2025, as well as fresh engineering agreements across major European infrastructure projects. See our latest analysis for Sweco. After a fairly subdued start to the year, Sweco’s recent wins in infrastructure contracts and its robust Q3 results have reignited investor interest. The stock posted a 7% share price return over the past month and 12% in the last 90...

Boliden AB recently commenced a share repurchase program and reported third quarter 2025 results, with sales of SEK 21.97 billion and net income of SEK 2.29 billion, alongside the announcement of board member Per Lindberg’s resignation due to personal reasons. The initiation of the buyback, intended to support future share delivery for participants in the company’s long-term incentive plan, could be seen as an indicator of management’s confidence in Boliden’s outlook and commitment to...

Bravida Holding AB (publ) recently reported third quarter and nine-month earnings for 2025, with sales reaching SEK 6,433 million and SEK 20,295 million respectively, and net income rising to SEK 244 million and SEK 739 million for the respective periods. Despite slightly lower sales, the company achieved higher net income and improved earnings per share, highlighting strengthened profitability for the latest periods. We’ll explore how this improvement in profitability may influence Bravida...

Cibus Nordic Real Estate has acquired the remaining 69.35% stake in Belgian property company One+ NV from TS33, becoming its sole owner, and entered into a new 50/50 joint venture, Two+ NV, focused on grocery-anchored assets in Belgium, while divesting three non-daily-goods properties. This activity consolidates Cibus's position in the Belgian market and secures a growth pipeline through the right of first refusal on TS33’s future retail developments. We'll look at how Cibus's full...

Epiroc (OM:EPI A) shares have caught investor attention with a mix of recent returns, including a dip over the past week after several months of steady growth. There is renewed curiosity about where the stock could head next. See our latest analysis for Epiroc. Despite a sharp 9.6% drop in its share price over the past week, Epiroc’s longer-term story is less volatile. Its one-year total shareholder return is holding just below neutral and its three- and five-year total returns show healthy...

Gränges (OM:GRNG) just released its third quarter earnings, revealing a jump in sales but a dip in net income compared to last year. The company also shared its outlook for the coming quarter, projecting ongoing sales volume growth even though demand in key markets remains soft. See our latest analysis for Gränges. Gränges has seen its share price steadily build momentum, most notably with a 16.3% share price return over the past month and a 6.2% climb in the last quarter, as investors weigh...

Munters Group recently announced it secured a significant order worth US$30 million (approximately SEK280 million) from a US-based commercial battery cell producer, featuring advanced LDP dehumidification systems for ultra-dry air environments. This order highlights growing demand for climate control technologies in critical battery production processes, reinforcing Munters’ position in high-spec industrial applications. We'll explore how this new contract for specialized battery cell...

Nordnet AB recently reported its third quarter and nine-month 2025 financial results, revealing year-over-year increases in net income and earnings per share to SEK 717 million and SEK 8.78, respectively. These results show solid improvements in profitability and indicate ongoing operational momentum as Nordnet continues to scale its digital savings and investment platform across the Nordics. We'll examine how Nordnet's continued earnings growth and margin expansion support or challenge its...

Ovzon (OM:OVZON) remains unprofitable but has managed to shrink its losses by 2.6% per year over the past five years. Looking ahead, revenue is forecast to rise 17.4% annually, far outpacing Sweden's broader market average of 3.8%, while earnings are projected to surge 78.47% per year, with profitability expected within three years. Despite these promising growth metrics, Ovzon’s price-to-sales ratio sits at 6.3x, which is significantly higher than both peer and industry averages and will...

Medicover recently announced additional results from the ongoing DART clinical study at Oslo University Hospital, highlighting the strength of its hybrid capture-based, tumour-agnostic MRD assay for minimal residual disease detection in unresectable stage III non-small cell lung cancer. The study’s findings showed that ctDNA detection could predict disease progression up to 7.4 months earlier than imaging, earning recognition with a Best Poster award at the European Society for Medical...

Hemnet Group (OM:HEM) just released its third quarter and nine-month results. Quarterly sales and net income dipped compared to last year, but nine-month numbers showed improvement. The company also wrapped up its latest share buyback tranche. See our latest analysis for Hemnet Group. Hemnet Group’s share price has lost momentum in recent months, with a 30-day share price return of -7% and a sharp 90-day drop of -26.2%. This reflects shifting sentiment after the buyback completion and a...

The board of RVRC Holding AB (publ) ( STO:RVRC ) has announced that it will be paying its dividend of SEK1.35 on the...